tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
US Market
DNTH
Dianthus Therapeutics
RESEARCH TOOLSreports

Dianthus Therapeutics (DNTH) Stock News & Sentiment

Compare
422 Followers
Dianthus Therapeutics Announces Major Public Equity Offering
Premium
Company Announcements
Dianthus Therapeutics Announces Major Public Equity Offering
7d ago
8K
DNTH
AI Integration Exposes Dianthus Therapeutics to Heightened Cyber, Privacy, and Reputational Risks
Premium
Company Announcements
AI Integration Exposes Dianthus Therapeutics to Heightened Cyber, Privacy, and Reputational Risks
10d ago
DNTH
Dianthus Advances Claseprubart With Positive Phase 3 Update
Premium
Company Announcements
Dianthus Advances Claseprubart With Positive Phase 3 Update
10d ago
8K
DNTH
Dianthus Therapeutics: Best-in-Class Complement Inhibitor Potential and Multiple 2026 Catalysts Support Buy Rating
Premium
Ratings
Dianthus Therapeutics: Best-in-Class Complement Inhibitor Potential and Multiple 2026 Catalysts Support Buy Rating
1M ago
DNTH
Dianthus Therapeutics: Multi-Indication Potential for Claseprubart Underpins Buy Rating Ahead of Key Phase II Readouts
Premium
Ratings
Dianthus Therapeutics: Multi-Indication Potential for Claseprubart Underpins Buy Rating Ahead of Key Phase II Readouts
1M ago
DNTH
Pipeline-in-a-Product Momentum: De-Risked Autoimmune Neurology Catalyst Path Justifies Buy Rating on Claseprubart Franchise
Premium
Ratings
Pipeline-in-a-Product Momentum: De-Risked Autoimmune Neurology Catalyst Path Justifies Buy Rating on Claseprubart Franchise
2M ago
DNTH
Dianthus Therapeutics: Clinical Momentum, Pipeline Expansion, and Undervalued Catalysts Support Buy Rating
Premium
Ratings
Dianthus Therapeutics: Clinical Momentum, Pipeline Expansion, and Undervalued Catalysts Support Buy Rating
2M ago
DNTH
More DNTH News >

DNTH News on the Web

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Minerva Neurosciences (NERV)
TipRanks News
Bullish
Dianthus price target raised to $103 from $80 at Wedbush
TipRanks News
Bullish
Dianthus Therapeutics Announces Major Public Equity Offering
TipRanks News
Neutral
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nanobiotix (NBTX), ImageneBio (IMA) and Dianthus Therapeutics (DNTH)
TipRanks News
Bullish
Dianthus 7.3M share Secondary priced at $81.00
TipRanks News
Bullish
Dianthus Therapeutics Raises $625 Million in Upsized Public Offering—What Does This Mean for Its Growth Ambitions?
Market Chameleon
Neutral
Dianthus Prices $625 Mln Offering To Advance Claseprubart And Broader Autoimmune Pipeline; Stock Up
rttnews
Bullish
Why Dianthus Therapeutics Stock Is Surging Today
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
DNTH
Sector Average
Media Buzz
This Week4 articles
Weekly Average11.75 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DNTH’s Media Buzz Sentiment?
4 articles about DNTH were published this week. In an average week, 11.75 articles are published.
    What is DNTH’s weekly average amount of articles?
    In an average week, 11.75 articles about DNTH are published.
      What is DNTH’s News Sentiment?
      100% of articles about DNTH were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        ABOSAcumen Pharmaceuticals
        IMMPImmutep
        ACETAdicet Bio
        LNSRLENSAR
        RPIDRapid Micro Biosystems
        Showing the stocks with the most bullish news sentiment over the past week